All Journals > Clinical Infectious Diseases > 15 December 2004 > Use of RZ for LTBI in Targeted Testing

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

15 December 2004

Volume 39, Number 12
Clinical Infectious Diseases 2004;39:1764–1771
1058-4838/2004/3912-0004$15.00
DOI: 10.1086/425610
MAJOR ARTICLE

Use of Intermittent Rifampin and Pyrazinamide Therapy for Latent Tuberculosis Infection in a Targeted Tuberculin Testing Program

David H. Priest,1

Louis F. Vossel, Jr.,2

Elizabeth A. Sherfy,2

Debbie P. Hoy,2 and

Connie A. Haley1,2

1Vanderbilt University School of Medicine and 2Tennessee Department of Health, Nashville, Tennessee

Background.To determine the rates of hepatotoxicity and treatment completion associated with intermittent rifampin and pyrazinamide (RZ) therapy for latent tuberculosis infection, we evaluated a cohort of patients from a targeted tuberculin testing site in Tennessee.

Methods.From 4 February 2000 through 9 November 2001, a total of 423 patients with latent tuberculosis infection received directly observed preventive therapy (DOPT) with RZ given twice weekly for 2 months. Most of the patients were young, Hispanic males who had recently immigrated to the United States.

Results.During treatment, hepatotoxicity developed in 29 patients (6.9%; hereafter refered to as “case patients”), and peak alanine aminotransferase (ALT) levels that were >10 times the upper limit of normal were noted in 18 case patients. Of the case patients, 14 had asymptomatic hepatotoxicity, and 2 required hospitalization; none of the case patients died. Hepatotoxicity developed after the receipt of 12 doses in more than half of the case patients, and 4 case patients received all 16 doses. The risk of RZ‐associated hepatotoxicity was independently associated with older age (odds ratio [OR], 1.07 per year; ). In total, 352 patients (83.2%) completed RZ therapy. The strongest predictors for noncompletion of RZ treatment were the development of a clinical symptom (OR, 9.73; ) and older age (OR, 1.08 per year; ).

Conclusions.Despite the use of DOPT, intermittent dosing, and vigilant monitoring throughout therapy, RZ was associated with an unacceptable risk of hepatotoxicity.

Received 20 April 2004; accepted 23 July 2004; electronically published 18 November 2004.

  • (See the editorial commentary by Blumberg on pages 1772–5)

Reprints or correspondence: Dr. Connie A. Haley, State of Tennessee Dept. of Health, 4th Fl., Cordell Hull Bldg., 425 5th Ave. N., Nashville, TN 37247‐4911 ().

Cited by

Kashef Ijaz, Peter D. McElroy, John Jereb, Thomas R. Navin, and Kenneth G. Castro. (2007) Safety of the Rifampin and Pyrazinamide Short-Course Regimen for Treating Latent Tuberculosis Infection. Clinical Infectious Diseases 44:3, 464-465
Online publication date: 1-Feb-2007.
Peter D. McElroy, Kashef Ijaz, and Thomas R. Navin. (2006) Reply to Cook. Clinical Infectious Diseases 42:6, 892-893
Online publication date: 15-Mar-2006.
Paul P. Cook. (2006) Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection. Clinical Infectious Diseases 42:6, 892-892
Online publication date: 15-Mar-2006.
Peter D. McElroy, Kashef Ijaz, Lauren A. Lambert, John A. Jereb, Michael F. Iademarco, Kenneth G. Castro, and Thomas R. Navin. (2005) National Survey to Measure Rates of Liver Injury, Hospitalization, and Death Associated with Rifampin and Pyrazinamide for Latent Tuberculosis Infection. Clinical Infectious Diseases 41:8, 1125-1133
Online publication date: 15-Oct-2005.
Susan K Lazerow, Maaza S Abdi, James H Lewis. (2005) Drug-induced liver disease 2004. Current Opinion in Gastroenterology 21:3, 283-292
Online publication date: 1-Jun-2005.
CrossRef
Henry M. Blumberg. (2004) Editorial Commentary: Treatment of Latent Tuberculosis Infection: Back to the Beginning. Clinical Infectious Diseases 39:12, 1772-1775
Online publication date: 15-Dec-2004.
Close Popup